Stargardt Disease clinical trials at UCLA
2 in progress, 1 open to eligible people
Tolerability and Effects of ALK-001 on Stargardt Disease
open to eligible people ages 8-70
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Los Angeles, California and other locations
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Sorry, in progress, not accepting new patients
To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).
Los Angeles, California and other locations
Our lead scientists for Stargardt Disease research studies include Steven Schwartz Michael Gorin, MD, PhD.
Last updated: